The Banking and Strategy Initiative

Chillin' out till it needs to be funded

Tag Archives: Synthes

US Economy: The more things change..(European inflation data)

Though Italian one year BOT on auction landed a cut off yield closer to 4% than the last 2.3% yield, the inflation thru the Eurozone more or less remained unchanged … Continue reading

June 13, 2012

Life, Illumina , Roche and Genomics – Building a $1000 genome map | Deal insight

Apparently the Roche hostile bid for industry expert Illumina is likely to be in the cross hairs of the Anti Trust office . That would be strange as the Genome … Continue reading

January 26, 2012

Advantage Dealbook: Upending that premium again, Gilead gets HCV portfolio

The culprit of course is another rrich Pharma company saturated with its current mdeicine/ device/service product opr package portfolio. After a J&J bid for Synthes that has  not progressed and … Continue reading

November 21, 2011 · 2 Comments

Investment Banking surviving on smaller deals

Image by Getty Images via @daylife According to BarCap’s Matt Ponsonby even as IB revenues for Banks depend most on M&A revenues esp Advisory  fees, the quantum of deals has been going … Continue reading

October 1, 2011 · 1 Comment

The Big Pharma rebuilding "decade": Is Big Pharma ready for the competition?

Well frankly, after our efforts to read up and check the air pressure on the Big Pharma machines, we find the restructuring effort in each case expensive and not worth … Continue reading

April 19, 2011 · 2 Comments

After Pfizer and Merck, J&J gets up to go | Advantage Dealbook

J&J has seen better days especially with brand rebuilding taking up the better part of 2010 and Pfizer and Glaxo running away with the honors with a Genzyme bid and … Continue reading

April 17, 2011 · 1 Comment

Archives